Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT06109311
- Locations
- 🇺🇸
MD First Research - Chandler, Chandler, Arizona, United States
🇺🇸Phoenix Clinical LLC, Phoenix, Arizona, United States
🇺🇸SanRo Clinical Research Group, Bryant, Arkansas, United States
A Study of [14C]-LOXO-783 in Healthy Adult Participants
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06102512
- Locations
- 🇺🇸
Fortrea Clinical Research, Madison, Wisconsin, United States
A Phase I Study of LY3502970 in Healthy Participants
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT06085482
- Locations
- 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT06075667
- Locations
- 🇺🇸
CenExel iResearch, LLC, Decatur, Georgia, United States
🇺🇸Solaris Clinical Research, Meridian, Idaho, United States
🇺🇸Cotton O'Neil Diabetes & Endocrinology, Topeka, Kansas, United States
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 405
- Registration Number
- NCT06074562
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Orange Grove Family Practice, Tucson, Arizona, United States
A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: [14C]-LY3556050
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT06052462
- Locations
- 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Moderate to Severe Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Eli Lilly & Co.
- Target Recruit Count
- 90
- Registration Number
- 2023-505608-43-00
- Locations
- 🇬🇷
University General Hospital Of Heraklion, Heraklion, Greece
🇬🇷Andreas Syngros Hospital Of Venereal And Dermatological Diseases, Athens, Greece
🇬🇷General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Greece
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1576
- Registration Number
- NCT06045221
- Locations
- 🇲🇽
Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
🇺🇸Absolute Clinical Research, Phoenix, Arizona, United States
🇺🇸San Fernando Valley Health Institute, Canoga Park, California, United States
A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT06049108
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT06047548
- Locations
- 🇺🇸
Cahaba Research - Pelham, Pelham, Alabama, United States
🇺🇸Velocity Clinical Research, Westlake, Los Angeles, California, United States
🇺🇸Southern California Dermatology, Inc., Santa Ana, California, United States